NASDAQ:PDEX - Pro-Dex Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $6.7170 -0.01 (-0.15 %) (As of 07/18/2018 12:19 PM ET)Previous Close$6.7241Today's Range$6.70 - $6.7552-Week Range$5.80 - $8.00Volume601 shsAverage Volume3,268 shsMarket Capitalization$28.95 millionP/E Ratio12.79Dividend YieldN/ABeta-0.3 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and machined parts. Further, it provides engineering consulting and placement services, as well as quality and regulatory consulting services. The company offers its products under the Pro-Dex brand name. Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, dental offices, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California. Receive PDEX News and Ratings via Email Sign-up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical SymbolNASDAQ:PDEX CUSIPN/A Webwww.pro-dex.com Phone949-769-3200 Debt Debt-to-Equity RatioN/A Current Ratio7.63 Quick Ratio5.90 Price-To-Earnings Trailing P/E Ratio12.79 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.94 million Price / Sales1.33 Cash Flow$1.3849 per share Price / Cash4.85 Book Value$3.42 per share Price / Book1.96 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$5.08 million Net Margins9.94% Return on Equity13.54% Return on Assets11.93% Miscellaneous Employees76 Outstanding Shares4,350,000Market Cap$28.95 Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions What is Pro-Dex's stock symbol? Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX." How were Pro-Dex's earnings last quarter? Pro-Dex Inc (NASDAQ:PDEX) announced its quarterly earnings data on Tuesday, February, 10th. The medical instruments supplier reported ($0.05) earnings per share for the quarter. The medical instruments supplier earned $2.80 million during the quarter, compared to analyst estimates of $2.60 million. Pro-Dex had a net margin of 9.94% and a return on equity of 13.54%. View Pro-Dex's Earnings History. What price target have analysts set for PDEX? 1 Wall Street analysts have issued 1 year target prices for Pro-Dex's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Pro-Dex's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 34.0% from the stock's current price. View Analyst Ratings for Pro-Dex. What is the consensus analysts' recommendation for Pro-Dex? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pro-Dex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of Pro-Dex's key competitors? Some companies that are related to Pro-Dex include Motus GI (MOTS), Sensus Healthcare (SRTS), Invuity (IVTY), Restoration Robotics (HAIR), Alphatec (ATEC), Invo Bioscience (IVOB), Neovasc (NVCN), Arch Therapeutics (ARTH), Spectral Medical (EDTXF), CAS Medical Systems (CASM), SANUWAVE Health, Inc. Common Stock (SNWV), iCAD (ICAD), Repro-Med Systems (REPR), Nephros (NEPH) and CELLECT BIOTECH/S (APOP). Who are Pro-Dex's key executives? Pro-Dex's management team includes the folowing people: Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 57)Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 48)Mr. Phillip S. Brown, VP & GM of OMSAngel Rebamontan Domingo, Director of Regulatory Affairs & Quality Assurance Has Pro-Dex been receiving favorable news coverage? Media stories about PDEX stock have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pro-Dex earned a media sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the medical instruments supplier an impact score of 44.54 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. How do I buy shares of Pro-Dex? Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pro-Dex's stock price today? One share of PDEX stock can currently be purchased for approximately $6.7170. How big of a company is Pro-Dex? Pro-Dex has a market capitalization of $28.95 million and generates $21.94 million in revenue each year. Pro-Dex employs 76 workers across the globe. How can I contact Pro-Dex? Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected] MarketBeat Community Rating for Pro-Dex (NASDAQ PDEX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 55 (Vote Outperform)Underperform Votes: 67 (Vote Underperform)Total Votes: 122MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What is a closed-end mutual fund (CEF)?